AMENDMENT TO THE CLAIMS

Please amend the claims as follows:

- ---Claims 1-11. (Cancelled)
- ---Claim 12. (Previously amended) A cross-linked hyaluronic acid derivative according to Claim 18 wherein the hydroxy groups of said hyaluronic acid derivative are sulphated or hemisucciny-lated---.
 - ---Claims 13 and 14. (Cancelled)
- ---Claim 15. (Previously amended) A pharmaceutical composition useful as (a) a substitute for synovial fluid in the treatment of osteoarthritic conditions and for vitreous humor in the treatment of pathologies and side effects connected in opthalmic surgery;

 (b) as a base for artifical tears formulation; (c) as a controlled release matrix of a medicament; and (d) as a healing and antiadhesive agent, in which the principal active ingredient is a cross-linked hyaluronic acid derivative according to Claim 18.
 - ---Claims 16 and 17. (Cancelled)
- ---Claim 18. (Currently amended) A hyaluronic acid derivative comprising cross-linked molecules of hyaluronic acid obtained by the reaction of the carboxylic acid groups of a hyaluronic acid wherein the cross-linkage occurs only through amide bonds between carboxy groups of the hyaluronic acid and the amino groups of a diamine of the formula NH₂-A-NH₂ wherein A is a linear unsubstituted C₂-C₆ chain or a polyoxyalkylene chain of the formula [(CH₂-O-CH₂)₂]_m wherein m is an interger from 2-10.
 - ---Claim 19. (Cancelled)